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A Case of Familial Juvenile Hyperuricemic Nephropathy with 
Novel Uromodulin Gene Mutation, a Novel Heterozygous 
Missense Mutation in Korea
Familial Juvenile hyperuricemic nephropathy (FJHN, OMIM #162000) is a rare autosomal 
dominant disorder characterized by hyperuricemia with renal uric acid under-excretion, 
gout and chronic kidney disease. In most but not all families with FJHN, genetic studies 
have revealed mutations in the uromodulin (UMOD) gene located on chromosome 
16p11-p13. We here described a novel heterozygous missense mutation (c.1382C>A 
causing p.Ala461Glu) in an affected 16-year-old male with hyperuricemia, gout and 
chronic kidney disease. His father was also affected and the UMOD mutation was found to 
segregate with the disease. There has been only one case report of Korean family with 
FJHN, which has not been diagnosed by genetic study. This is the first report of genetically 
diagnosed FJHN in Korea. 
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Nephrology
INTRODUCTION
Familial juvenile hyperuricemic nephropathy (FJHN, OMIM 
#162000) is a rare autosomal dominant disorder characterized 
by hyperuricemia, gout and chronic kidney disease (1-4). It was 
first described by Duncan and Dixon in 1960 and more than 50 
families in various ethnic groups have been described (5). How-
ever, there has been no report about precise incidence and prev-
alence of FJHN. The hyperuricemia, which is associated with 
decreased urinary excretion of urate, is known to causes chron-
ic kidney disease in most patients. Affected family members show 
the impairment of urate excretion before puberty and usually 
develop hyperuricemia and gout after adolescence (6). Renal 
function gradually deteriorates and results in end-stage renal 
disease within 10 to 20 years. Diagnosis is suggested by a frac-
tional excretion of uric acid of <5% (normal, 10-15%) with the 
symptoms and signs of FJHN (7). 
  The gene causing FJHN has been mapped to chromosome 
16p11-p13 and in close proximity to the gene for medullary cys-
tic kidney disease type 2 (MCKD2, OMIM #603860) (2). Muta-
tions of the gene encoding uromodulin (UMOD) have been re-
ported in several studies about various ethnic FJHN families. 
Eiji et al. reported five separate heterozygous missense muta-
tions of the UMOD gene in five Japanese families with FJHN (1). 
Stacey et al. pursued linkage studies in seven European families 
with FJHN. But two of seven families were found not to be linked 
to chromosome 16p11-p13, thereby demonstrating genetic het-
erogeneity in more than 25% of FJHN families (8). Its clinical and 
histologic features are similar to those of MCKD type 2. Recent 
genetic studies revealed that MCKD type 2 is also associated with 
mutations in the UMOD gene, therefore an opinion is emerging 
that FJHN and MCKD type 2 are not the different diseases (9). 
  It is not clear what pathologic role of mutations of UMOD gene 
as a cause of renal urate under-excretion in FJHN. We found a 
Korean family with FJHN and five male members of them had 
gout and chronic kidney disease, which were diagnosed at teen-
age. There has been only one FJHN case report of Korean family 
without genetic analysis (10). This is the first report of genetical-
ly diagnosed FJHN in Korea. 
CASE REPORT
A 16-yr-old male had been suffered from waxed and waned 
symptoms of swelling and pain of right 1st metatarsal joint since 
his age of 14. Recently he was hospitalized at a local clinic due 
to same symptoms, and was diagnosed as hyperuricemia, gouty 
arthritis and renal insufficiency. Though his symptoms were 
resolved with prednisolone, he was transferred to nephrology 
department of our hospital for further evaluation on abnormal 
renal function (April 4, 2009). On admission, he reported stable 
vital signs and no symptoms associated with azotemia. On phys-
ical examinations, he had no peripheral edema. Electrocardig-Lee DH, et al.  •  A Case of Familial Juvernile Hyperuricemic Nephropathy
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raphy and simple radiography showed normal findings. The 
blood urea nitrogen was 17.5 mg/dL, serum creatinine was 1.59 
mg/dL. Laboratory tests revealed hyperuricemia (uric acid 11 
mg/dL) and renal under-excretion of urate (fractional excretion 
of uric acid 3.13%; 24 hr urine uric acid 327 mg). Serum total 
protein was 7.6 g/dL, albumin was 4.7 g/dL and total cholester-
ol was 161 mg/dL. Other laboratory tests showed results within 
normal range. There were no abnormal urinary findings like 
hematuria, proteinuria and pyuria. Abdominal sonography 
showed normal size and echogenicity in both kidneys, and no 
other structural abnormality was found. A renal biopsy was not 
performed. 
  In the family history, his elderly brother was diagnosed with 
gout and renal insufficiency at age 18. Kidney biopsy, which was 
performed at his age of 20 in one hospital, revealed tubuloint-
erstitial disease. His grandfather, father and uncle were also di-
agnosed with gout and chronic kidney disease at teenage and 
they have been treated with allopurinol for several years (Fig. 1). 
All of them had no other chronic disease such as hypertension 
or diabetes. 
  Two peripheral blood samples for gene analysis were ob-
tained from patient and his father. DNA sequence analysis of 
the 10 exons of the UMOD gene was undertaken for genetical 
confirmation of FJHN. Gene analysis revealed a novel heterozy-
gous missense mutation (c.1382C>A, p.Ala461Glu) that altered 
evolutionary conserved residues in the gene encoding UMOD 
(Fig. 2). Detected mutation was located in exon 6. The patient 
has been treated with allopurinol (100 mg/day) since admis-
sion and patient’s serum uric acid level begun to decrease. Ten 
months later, his serum uric acid level was 6.4 mg/dL and se-
rum creatinine level was 1.63 mg/dL. He remained clinically 
asymptomatic throughout this period. In this family, other af-
fected members were treated with allopurinol and their serum 
uric acid levels were maintained. None of them developed end 
stage renal disease.
DISCUSSION
In most but not all families with FJHN, genetic studies have re-
vealed mutations in the UMOD gene located on chromosome 
16p11-p13. Many studies revealed various heterozygous mis-
sense mutations in the UMOD gene of families with FJHN. Uro-
modulin, which is also called Tamm-Horsfall protein, is the most 
abundant protein in normal urine and a major component of 
urinary casts. Uromodulin is synthesized exclusively and abun-
dantly in the thick ascending limb of the loop of Henle and is 
known to have a pro-inflammatory potential such as activation 
of neutrophil, stimulation of monocyte to proliferate and release 
cytokines and gelatinases. UMOD gene knockout mice showed 
difficulty in clearing bacteria from the urinary bladder (11). Sev-
eral studies have demonstrated reduced levels of UMOD in the 
urine of patients with FJHN and other studies have reported tu-
bulointerstitial immune complex nephritis in rats immunized 
with UMOD protein (12, 13). Therefore, in the past it was simply 
thought that pro-inflammatory potential of UMOD protein might 
be related with the tubulointerstitial nephritis in FJHN. However, 
another recent study revealed that patients with FJHN who did 
not have UMOD mutations still showed reduced urinary excre-
tion of uromodulin (14). Gersch et al. (15) also reported that 
UMOD knockout mice did not develop hyperuricemia. Howev-
er, precise functions of UMOD still remain obscure and it is also 
not clear how mutations in the UMOD gene affect decreased 
urate excretion in patients with FJHN. Karin et al. reported there 
was a markedly increased expression of UMOD in a cluster of 
tubule profiles, suggesting an accumulation of the protein in 
tubular cells in families with FJHN and they also showed de-
creased urinary excretion of wild-type uromodulin (12). Jen-
Fig. 1. Pedigree of a family with familial juvernile hyperuricemic nephropathy. An 
arrow represents a patient of this case report. Underlines represent individuals who 
supplied DNA samples.
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Fig. 2. Uromodulin (UMOD) gene analysis in the patient and his father. (A) Sequence 
of the patient with exon 6 c.1382C>A heterozygous missense mutation (arrow). (B) 
The same mutation (arrow) sequenced in his father. Lee DH, et al.  •  A Case of Familial Juvernile Hyperuricemic Nephropathy
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nings et al. (16) recently reported wild type and mutant uro-
modulin cDNA constructed in polarized monolayers of cultured 
kidney cell and found that both wild type and mutant uromod-
ulin protetin were secreted more on the apical than the basolat-
eral side of the monolayers . The author also reported the apical 
secretion of the mutant uromodulin was reduced, whereas the 
basal secretion was unaffected, suggesting that the mutant uro-
modulin in kidneys of patients with FJHN might elicit an im-
mune response to uromodulin, which results in tubular injury 
and interstitial fibrosis. 
  Controversy exists as to whether lowering serum uric acid 
slows the progression of renal failure; the studies reporting ben-
efit have usually involved starting a xanthine oxidase inhibitor 
early in the course of the disease (8). In the present FJHN fami-
ly, a single nucleotide substitution was found to cause a hetero-
zygous missense mutation (c.1382C>A, p.Ala461Glu) in exon 6, 
which had not been described previously. The present family 
members with gout and chronic kidney disease have been treat-
ed with allopurinol during several years and their serum uric 
acid levels have been maintained within normal range. None of 
them developed end stage renal disease. However, genetic anal-
ysis was not performed in unaffected members of the present 
FJHN family. In the present FJHN family, all five male members 
with hyperuricemia and chronic kidney disease were treated 
with allopurinol and their serum uric acid levels were main-
tained. All of them showed reduced renal function (40-60 mL/
min/1.73 m
2), however none of them developed end stage re-
nal disease.
  In conclusion, we observed a FJHN family confirmed by ge-
netic analysis for the first time in Korea. Genetic analyses show 
UMOD gene mutation, a novel heterozygous missense mutation 
(c.1382C> A, p.Ala461Glu), which has not been reported previ-
ously. 
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